28th Annual John Goldman Conference on
CHRONIC MYELOID LEUKEMIA: BIOLOGY AND THERAPY
October 2-4, 2026 – Gothenburg, Sweden

Chairs: J. Cortes, T.P. Hughes, D.S. Krause
Co-Organizers: R. Bhatia, T. Brümmendorf, M. Copland, M. Deininger, O. Hantschel, V. Helgason, S. T. Ong, J. Radich, D. Réa

Advisory Committee: J. Apperley, S. Branford, C. Gambacorti-Passerini, F. Guilhot, R. Hehlmann, P. Laneuville, F-X. Mahon, G. Saglio, S. Soverini, PR. Van Etten

Friday, October 2, 2026

08:15-08:20	**Welcome**	Jorge Cortes (Birmingham, AL)
08:20-08:25	**Welcome to Gothenburg**	Anna Lübking (Lund)
08:25-08:35	**iCMLf - A review**	Jorge Cortes (Birmingham, AL)

SCIENTIFIC SESSION 1: TOP SCORING ABSTRACTS 2026 *(12' + 3' discussion)*
Chairs: François-Xavier Mahon (Bordeaux), Tiffany Ricketts (Birmingham, AL)

08:35-08:50	Serine and Glycine restriction induces acute metabolic dysfunction and enhances clearance of therapy-resistant leukaemic stem/progenitor cells in vivo	Stephen E Wilkie (Glasgow)
08:50-09:05	An immature and exhausted NK/T-cell profile precedes molecular relapse and predicts treatment-free remission failure: data from the DES-CML Brazilian trial	Larissa Binelli (Campinas)
09:05-09:20	CD35 defines apex hematopoietic stem cells whose preservation predicts tyrosine kinase inhibitor response in CML	Ram Thakur (Lund)
09:20-09:35	Co-variates associated with success of sustained Therapy-Free Remission in chronic myeloid leukaemia	Qian Jiang (Beijing)
09:35-09:50	Continued Improved tolerability of Asciminib vs Nilotinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): results from the phase 3b ASC4START trial	Susanne Saussele (Mannheim)
09:50-10:05	Single-cell genetic lineage tracing reveals pre-existing blast crisis-initiating clones at chronic phase CML diagnosis	Sin Tiong Ong (Singapore)

10:05-10:35 Coffee Break

TESSA HOLYOAKE MEMORIAL LECTURE: SPECIAL LECTURE (1) *(20' + 5' discussion)*
Chair: Rüdiger Hehlmann (Weinheim)

10:35-10:55	25 years of TKI	Jane Apperley (London)
10:55-11:00	*Discussion*	

SCIENTIFIC SESSION 2: Microenvironment
Chair: Richard Van Etten (Irvine)

11:00-11:15	**Keynote Presentation:** Chronic myeloid leukemia and the bone marrow microenvironment	Daniela S. Krause (Mainz)
11:15-11:20	*Discussion*	
	Selected Abstracts: *(12' + 3' discussion)*	
11:20 -11:35	Macrophage engagement of CD44 promotes chronic myeloid leukemia stem cell growth	Tiffany Ricketts (Birmingham)
11:35-11:50	Bone marrow endothelial progenitor cells drive TKI resistance in CML via SEMA4D-Plexin B1-mediated metabolic reprogramming	Shunjie Yu (Beijing)
11:50-12:05	MyD88 inhibition using a chemical analogue of a parasitic helminth glycoprotein eradicates TKI resistant cells and inflammatory leukaemia stem cells	Thanatpornpat Kritalug (Glasgow)
12:05-12:15	**JANET ROWLEY PRIZE PRESENTATION** **Presenter:** Michael Deininger (Ann Arbor) **Awardee 2026:** Junia V. Melo (Adelaide)	

JANET ROWLEY PRIZE: SPECIAL LECTURE (2)
Chair: Michael Deininger (Ann Arbor)

12:15-12:35	CML: when BCR::ABL1 was just BCR-ABL	Junia V. Melo (Adelaide)
12:35-12:40	*Discussion*	

12:40-14:40 Lunch and Poster Viewing

13:30-14:30 **SATELLITE SYMPOSIUM**
Planning ahead in CML: how early decisions shape long-term outcomes and life goals
Chair: Anna Lübking (Lund)
Speakers: Delphine Réa (Paris), Elisabetta Abruzzese (Rome)

This symposium is organized and sponsored by Novartis

MICHELE BACCARANI SPECIAL SYMPOSIUM *(12' + 5' discussion)*
SIGNIFICANCE AND ASSESSMENT OF MRD IN VARIOUS HEMATOLOGIC DISORDERS
Chair: Nick Cross (Southampton)

14:40-14:50	Introductory overview – concepts and challenges	
14:50-15:07	The evolution of MRD assessment in hematologic malignancies	Jerald Radich (Seattle)
15:07-15:24	MRD-oriented approaches in ALL	Robin Foà (Rome)
15:24-15:41	MRD as a therapeutic target in AML	Richard Dillon (London)
15:41-15:58	Cell kinetics and MRD-directed outcomes in CLL	Othman Al-Sawaf (Cologne)
15:58-16:15	MRD in CML: what really matters (and why)	Susan Branford (Adelaide)
16:15-16:45	General Discussion	

16:45-17:15 Coffee Break

SPECIAL LECTURE (3):
Chair: Ravi Bhatia (Birmingham, AL)

17:15-17:35	Inherited resilience to clonal hematopoiesis by modifying stem cell RNA regulation	Gaurav Agarwal (Oxford)
17:35-17:40	*Discussion*	

SCIENTIFIC SESSION 3: Immunology and stem cells
Chair: Mhairi Copland (Glasgow)

17:40-17:55	**Keynote Presentation:** Immune mechanisms in CML: where do we stand and where do we go now	Agnes Yong (Perth)
17:55-18:00	*Discussion*	

Selected Abstracts: *(12' + 3' discussion)*

18:00-18:15	Selective targeting of leukaemic stem cells in CML via dual-marker bispecific antibody immunotherapy	Zsombor Kerekes (Glasgow)
18:15-18:30	Signaling through TNFRSF1A enhances the competitive advantage of CML LSCs relative to normal HSCs during TKI treatment	Tyler Freeland (Birmingham, AL)
18:30-18:45	Early prediction long-term molecular response in chronic myeloid leukemia using plasma drug concentration and single-cell immune and signaling profiles	Stein-Erik Gullaksen (Bergen)

18:50-20:30 **Poster Viewing and Welcome Get-Together**

- *Biology Poster Leader: Stein-Erik Gullaksen (Bergen)*
- *Clinical Poster Leaders: Dragana Milojkovic (London), Kendra Sweet (Tampa)*

Saturday, October 3, 2026

WORKSHOP FOR NON-CLINICAL SCIENTISTS #1: Glycobiology in hematopoiesis
Chairs: Michael Deininger (Ann Arbor), Daniela S. Krause (Mainz)

07:30-07:35	Introduction	
07:35-08:00	Glycobiology in hematopoiesis: from stem cells to megakaryocyte dysplasia, thrombocytopenia, and cancer	Karin Hoffmeister (Milwaukee)
08:00-08:10	*Discussion*	
08:10-08:35	Antibody and cellular glycomics of hematological disorders	Manfred Wuhrer (Leiden)
08:35-08:45	*Discussion*	
08:45-09:10	Integrating glycomics and functional genomics to reveal new targets for immunotherapy in myeloid leukemia	Simon Wisnovsky (Vancouver)
09:10-09:20	*Discussion*	
09:20-09:30	Conclusion	

08:45-09:45 **CONCURRENT MEET-THE-EXPERT SESSIONS (pre-registration required)**
1. How do I choose frontline therapy? – Massimo Breccia (Roma) and Hemant Malhotra (Jaipur)
2. Blast phase – Mhairi Copland (Glasgow) and Michael Mauro (New York)

09:30-10:00 Coffee Break

SCIENTIFIC SESSION 4: Resistance and transformation
Chair: Simona Soverini (Bologna)

10:00-10:15	**<u>Keynote Presentation</u>:** Understanding and overcoming resistance to TKIs	Oliver Hantschel (Marburg)
10:15-10:20	*Discussion*	
	Selected Abstracts: *(12' + 3' discussion)*	
10:20-10:35	Structural analysis of class II asciminib resistance mutations of BCR::ABL1	Inga B. Leske (Marburg)
10:35-10:50	Additional gene fusions and specific deletions at treatment failure are strongly associated with subsequent development of blast phase, whereas ASXL1 variants alone at treatment failure do not carry that risk	Susan Branford (Adelaide)
10:50-11:05	Integrated genomic and transcriptomic analyses reveal biological heterogeneity of accelerated-phase chronic myeloid leukemia and identify a blast-phase-like subgroup	Xiaoshuai Zhang (Beijing)

11:05-11:20	Quantum pharmacophore modeling identifies synergy between LY3009120 and asciminib to inhibit BCR::ABL1 compound mutants	Michael Deininger (Ann Arbor)
11:20-11:35	The timing of ELN "warning" predicts transition to "unfavorable" in chronic-phase CML	Fumisato Takagi (Hamamatsu)

SPECIAL LECTURE (4):
Chair: Sin Tiong Ong (Singapore)

11:35-11:50	Overview on what ASXL1 is doing	Toshio Kitamura (Tokyo)
11:50-12:00	*Discussion*	

12:00-13:55 Lunch and Poster Viewing

12:45-13:45 **CONCURRENT MEET-THE-EXPERT SESSIONS (pre-registration required)**
1. Role of transplant in CML today – Jane Apperley (London) and Vivian Oehler (Seattle)
2. MRD – Othman Al-Sawaf (Cologne) and Richard Dillon (London)
3. Pediatrics in CML – Nirmalya Roy Moulik (Mumbai) and Meinolf Suttorp (Dresden)

<u>DEBATE</u>: Are we too obsessed with achieving TFR, often to the detriment of the patient?
Chair: Jorge Cortes (Birmingham, AL)

13:55-14:00 Introduction

Audience votes

14:00-14:10	We push too hard	Tim Brümmendorf (Aachen)
14:10-14:20	We should push for the TFR as much as possible	Tim Hughes (Adelaide)
14:20-14:35	*Discussion*	

Audience votes again

SCIENTIFIC SESSION 5: Clinical trials
Chair: Ehab Atallah (Milwaukee)

14:35-14:50	**<u>Keynote Presentation</u>:** New, newer and newest TKI: what is their role in the treatment of CML in the next decade	Andreas Hochhaus (Jena)
14:50-14:55	*Discussion*	

Selected Abstracts: *(12' + 3' discussion)*

14:55-15:10	ENABLE: Efficacy and safety of ELVN-001, a novel, selective ATP-competitive inhibitor of BCR::ABL1, in patients with previously treated chronic phase (CP)-chronic myeloid leukemia (CML)	Dragana Milojkovic (London)

15:10-15:25	Asciminib once or twice daily demonstrates sustained efficacy and favorable safety in patients with chronic myeloid leukemia resistant or intolerant to prior TKIs: End of study results from ASC4OPT	Massimo Breccia (Rome)
15:25-15:40	Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: final outcomes of the RODEO study	Nienke Lokhorst (Nijmegen)
15:40-15:55	Updated efficacy and safety of TGRX-678, a novel STAMP inhibitor, in heavily pretreated TKI-resistant/intolerant CML patients from phase 1 study	Qian Jiang (Beijing)
15:55-16:10	Evaluation of cognitive functions in patients with chronic myeloid leukemia Under tyrosine kinase inhibitor therapy	Seymen Dobur (Istanbul)

16:10-16:40 Coffee Break

16:40-16:50 **JOHN GOLDMAN PRIZE PRESENTATION**
Presenter: Andreas Hochhaus (Jena)
Awardee 2026: Meinolf Suttorp (Dresden)

JOHN GOLDMAN PRIZE: SPECIAL LECTURE (5)
Chair: Andreas Hochhaus (Jena)

16:50-17:10	CML in the first two decades of life - a pediatrician's viewpoint	Meinolf Suttorp (Dresden)
17:10-17:15	*Discussion*	

17:20-18:50 ***Poster Viewing***
- *Biology Poster Leader: Stein-Erik Gullaksen (Bergen)*
- *Clinical Poster Leaders: Dragana Milojkovic (London), Kendra Sweet (Tampa)*

Sunday, October 4, 2026

07:00-08:00 John Goldman charity Fun Run, organized by the iCMLf (Pre-registration required)

WORKSHOP FOR NON-CLINICAL SCIENTISTS #2: Biology around cell death
Chairs: Ravi Bhatia (Birmingham, Alabama), Vignir Helgason (Glasgow)

09:00-09:05	Introduction	
09:05-09:30	Mitochondrial apoptosis/BH3 profiling	Triona Ni Chonghaile (Dublin)
09:30-09:40	*Discussion*	
09:40-10:05	Cell death and how it shapes anti-tumour immune responses	Stephen Tait (Glasgow)
10:05-10:15	*Discussion*	

10:15-10:40	Regulation of ferroptosis	Jose Pedro Friedmann Angeli (Würzburg)
10:40-10:50	*Discussion*	
10:50-11:00	Conclusion	

SCIENTIFIC SESSION 6: TFR
Chair: Delphine Réa (Paris)

09:10-09:25	**Keynote Presentation:** Have we reached a ceiling in TFR success?	Susanne Saussele (Mannheim)
09:25-09:30	*Discussion*	
	Selected Abstracts: *(12' + 3' discussion)*	
09:30-09:45	Sustained treatment-free remission beyond 10 years in chronic myeloid leukemia: a real-world cohort supporting the concept of operational cure	François-Xavier Mahon (Bordeaux)
09:45-10:00	High rates of successful second stop attempts in patients with chronic myeloid leukemia: results of the NAUT trial	Susanne Saussele (Mannheim)
10:00-10:15	Discontinuation of tyrosine kinase inhibitors following prior two-step dose reduction: results of the Czech nationwide HALF study in patients with chronic myeloid leukemia	Daniela Zackova (Brno)

10:15-10:45 Coffee Break

10:45-10:50 **BEST POSTER CEREMONY**
Chair: Jorge Cortes (Birmingham, AL)

SPECIAL LECTURE (6):
Chair: Carmen Fava (Turin)

10:50-11:10	Microbiome, inflammation, and GVHD in the setting of allogeneic transplantation	Pavan Reddy (Houston)
11:10-11:15	*Discussion*	

ESH INTERNATIONAL JOHN GOLDMAN RESEARCH AWARD CEREMONY 2026
Chair: Daniela Krause (Mainz)

11:15-11:20	Announcing the Awardee 2026	
11:20-11:30	Splicing-driven telomere vulnerability as a biomarker and therapeutic target in myelofibrosis	Mariela Cortés López (Munich)
11:30-11:35	*Discussion*	
11:35-11:45	**iCMLf PRIZE PRESENTATION:** **Presenter:** Giuseppe Saglio (Turin) **Awardees 2026:** Amha Gebremedhin (Addis Ababa)	

iCMLf PRIZE: SPECIAL LECTURE (7)
Chair: Giuseppe Saglio (Turin)

11:45-12:05 Chronic myeloid leukemia in Ethiopians — Amha Gebremedhin (Addis Ababa)
12:05-12:10 *Discussion*

12:10-12:15 Closing Remarks

MEETING CLOSURE